3 Articles
3 Articles
AstraZeneca Plc acquires EsoBiotec in $1bn cell therapy deal
AstraZeneca Plc (LON:AZN) has announced the successful completion of the acquisition of EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity. The EsoBiotec Engineered NanoBody Lentiviral (ENaBL) platform empowers the immune system to attack cancers and could offer many more patients access to transformative cell therapy treatments delivered in just minutes rather than the cu…
AstraZeneca agrees £750m deal for EsoBiotec
AstraZeneca has agreed a deal to acquire EsoBiotec for up to £750m. The acquisition includes the Belgian firm’s in vivo delivery platform, which the Cambridge pharma giant said has the potential to transform cell therapy. The EsoBiotec Engineered NanoBody Lentiviral (ENaBL) platform empowers the immune system to attack cancers and could offer many more patients access to transformative cell therapy treatments delivered in just minutes rather tha…
Coverage Details
Bias Distribution
- 100% of the sources lean Left
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage